ZUG, SWITZERLAND, 25 February 2025 – PSI CRO announces the addition of more powerful GenAI for protocol similarity search and enrollment rate predictions and integration of three new data sources in their VISIONAL™ feasibility/financial planning platform. VISIONAL™ is part of PSI’s INTELIA™ platform, which includes a suite of advanced tools for clinical trial modeling and planning.
The two main improvements in this update showcase:
- Increased precision: AI search helps find similar protocols in just a few minutes. Instead of relying on high-level data and often unreliable industry benchmarks, VISIONAL™ now quickly pulls the most valuable site performance data in 56 countries. Then, the system compares this data with established benchmarks and offers options and interpretations for both feasibility and operational teams. The data is fully automated, and humans in the loop make the final, data-driven, decisions.
- Enhanced speed: With the new, enhanced GenAI search and data integration, PSI can develop credible multi-country scenarios with budgets for sponsors in less than half an hour. PSI uses VISIONAL™ already at study proposal generation, allowing sponsors flexibility and ease of mapping out various clinical trial scenarios during the dynamically evolving planning stage.
Launched in 2022, VISIONAL™ is one of the most comprehensive feasibility/financial planning platforms in the industry. Through a combination of machine learning for budget forecasting, business-weighted constraint-based algorithms for scenario modeling, and generative AI (GenAI) for protocol similarity search and enrollment rate prediction, INTELIA™ helps sponsors get control over clinical trial planning.
About PSI
PSI CRO is a global full-service contract research organization (CRO), committed to being the best CRO in the world as measured by its employees, customers, investigators, and vendors. PSI’s key operational differentiator is on-time delivery of clinical trials. This metric remained above 90% in 2024.
The company specializes in pivotal phase 2 and phase 3 clinical trials in oncology, hematology, gastroenterology, autoimmune, infectious diseases, neurology, and other indications. PSI provides expertise in complex trials at the forefront of precision medicine, including platform and umbrella designs, trials in targeted immunotherapy, radiopharmaceuticals, and cell and gene therapies.
In 2025, PSI is celebrating its 30th year of business as the only fully independent and privately owned mid-sized CRO. PSI employs over 3,000 people across 56 countries as of December 31, 2024. Global headquarters are in Switzerland at 113a Baarerstrasse, Zug 6300.
For more information, visit www.psi-cro.com.
For Media Inquiries
Paul Mirek
